Bifogade filer
Insider information: Revenio raises estimates for 2022
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | Large Cap Helsinki |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Revenio Group Corporation, Insider information, January 26, 2023 at 1.45 p.m. (EET)
Insider information: Revenio raises estimates for 2022
Revenio Group Corporation announces information on Q4 and full year financial performance and raises estimates for 2022.
According to guidance published on February 10, 2022, Revenio Group Corporation estimated that its exchange rate-adjusted net sales would grow strongly from the previous year and profitability, excluding non-recurring items, would remain at a good level. According to preliminary unaudited information, Revenio’s net sales and operating profit are better than estimated. The company estimates that the exchange rate-adjusted net sales for the year 2022 will grow above 16 percent from the previous year and that operating profit (EBIT), excluding non-recurring items, will be above 30 percent of net sales. Especially the stronger-than-expected Q4 sales increased the company’s net sales, which exceeded previous guidance. Simultaneously, Revenio’s scalable business model reacted to the strong increase in net sales, resulting in the company’s profitability to exceed guidance as well.
During the silent period, the company does not comment on or disclose other preliminary information on its performance before the publication of its financial statement bulletin. Revenio will publish its 2022 financial statement bulletin on Thursday, February 9, 2023 around 9.00 a.m.
Revenio Group Corporation
For further information, please contact
Jouni Toijala, CEO, tel. +358 50 484 0085
jouni.toijala@revenio.fi
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
Distribution
Nasdaq Helsinki
FIN-FSA
Key media
www.revenio.fi/en
Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.